The Role of Proteinase-Activated Receptors 1 and 2 in the Regulation of Periodontal Tissue Metabolism and Disease

E. S. Rovai and M. Holzhausen

Division of Periodontics, Department of Stomatology, School of Dentistry, University of São Paulo, São Paulo, SP, Brazil

Correspondence should be addressed to M. Holzhausen; marinella@usp.br

Received 16 November 2016; Revised 13 January 2017; Accepted 5 March 2017; Published 19 April 2017

Copyright © 2017 E. S. Rovai and M. Holzhausen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Proteinase-activated receptors 1 (PAR1) and 2 (PAR2) are the most highly expressed members of the PAR family in the periodontium. These receptors regulate periodontal inflammatory and repair processes through their activation by endogenous and bacterial enzymes. PAR1 is expressed by the periodontal cells such as human gingival fibroblasts, gingival epithelial cells, periodontal ligament cells, osteoblasts, and monocytic cells and can be activated by thrombin, matrix metalloproteinase 1 (MMP-1), MMP-13, fibrin, and gingipains from Porphyromonas gingivalis. PAR2 is expressed by neutrophils, osteoblasts, oral epithelial cells, and human gingival fibroblasts, and its possible activators in the periodontium are gingipains, neutrophil proteinase 3, and mast cell tryptase. The mechanisms through which PARs can respond to periodontal enzymes and result in appropriate immune responses have until recently been poorly understood. This review discusses recent findings that are beginning to identify a cardinal role for PAR1 and PAR2 on periodontal tissue metabolism.

1. Introduction

Periodontium is characterized by the tissues that involve and support the teeth such as the gingiva, alveolar mucosa, cementum, periodontal ligament, and alveolar bone. Periodontitis, an oral disease which leads to alveolar bone loss, can be mediated by some of the endogenous host enzymes, as well as bacterial proteinases present in the periodontal pocket (e.g., neutrophil serine proteinase 3), mast cell tryptase, and gingipain from Porphyromonas gingivalis. Interestingly, it was recently shown that the biological activities of these proteinases can be mediated through specific proteinase-activated receptor (PAR) activation. PARs are members of the G-protein-coupled family, seven-transmembrane domain receptors, and their activation occurs through proteolytic cleavage of the N-terminal domain by proteinases, leading to the generation of a new N-terminal “tethered ligand,” which binds to the receptor itself resulting in its autoactivation [1, 2]. Until now, four members of the PAR family were discovered: PAR1, PAR2, and PAR3, which are activated by thrombin and PAR2 that can be activated by trypsin, neutrophil proteinase 3, tissue factor/factor VIIa/factor Xa, mast cell tryptase, membrane-tethered serine proteinase-1, or gingipains [3, 4]. PARs represent a component of the innate inflammatory response, being involved in neutrophil recruitment, increased perfusion, pain, and swelling. Thus, since PARs are present in periodontal epithelial cells and are capable of recognizing and responding to bacterial infections, it is believed that they can act as a first “alarm system” for bacterial invasions [5]. In addition, studies have suggested an important role for PARs in regulating the inflammatory response intensity to bacterial infection, as well as in periodontitis [5, 6].

Although the structures and mechanisms related to the activation of these receptors are similar, they can be expressed by different cells; hence, in each cell, their activation may lead to distinct roles in pathophysiological processes, such as growth, development, inflammation, tissue repair, and pain [2, 7–10]. PAR1 is expressed by platelets, osteoblast endothelial cells, epithelial cells, fibroblasts, myocytes, neurons, and astrocytes, and it seems to play an important role in injured tissues. In the periodontium, the literature have also implicated PAR1 in bone repair and homeostasis [11–13], as well as proliferation of gingival fibroblasts mediated by the
protein synthesis of endothelin-1 (ET-1) and subsequent activation of ET receptor type A [14] and transactivation of latent transforming growth factor beta 1 (TGF-β1) [15]. In addition, Rohani et al. [16] showed that in gingival epithelial cells, the PAR1 activation by thrombin can result in the induction of chemokines leading to granulocyte attraction. Interestingly, gingipain-R (RgpB and HRgpA), a protease from Porphyromonas gingivalis, can activate PAR3 in monocytic cells triggering an overproduction of proinflammatory cytokines [17] and in the surface of platelets leading to platelet aggregation [18]. This mechanism may constitute the biological plausibility of the association between periodontitis and cardiovascular disease and deserves further clarification by future studies.

PAR3 and PAR4 are expressed by platelets, endothelial cells, myocytes, and astrocytes, and their activation has been associated with the formation of pathologic thrombus [1]. The functional role of PAR1 is controversial, whereas some investigators have described it as a nonsignaling receptor that acts along with PAR4 and PAR6, others have claimed that PAR3 can signal independently of PAR1 activation. Thus, since PAR1 and PAR4 are less abundant than PAR3, in periodontal cells, and since their possible function on the periodontium still needs to be investigated [16], they are not going to be part of the present review.

PAR1 has been demonstrated to be expressed by epithelial cells, endothelial cells, fibroblasts, osteoblasts, myocytes, neurons, astrocytes, lymphocytes, neutrophils, and mast cells [1, 17, 19–21], where it has been associated to several roles in the inflammation process such as increased vascular permeability, blood vessel relaxation, hypotension, granulocyte infiltration, release of cytokines, and pain [3, 4, 17, 22–26]. Moreover, inflammatory events in the joints, skin, colon, kidney, and airways have also been associated to PAR2 activation [1, 2, 24, 27–29]. More recently, studies have shown that PAR2 activation may play an important role in the inflammatory process and tissue breakdown in periodontitis [6, 30–33].

In this review, we will discuss the possible roles of the most highly expressed members of the PAR family in the periodontium, PAR1 and PAR2, as important molecules that mediate mammalian and bacterial enzyme’s effects on cells in the regulation of periodontal inflammation and repair.

2. Potential Activators of PARs and Their Inhibitors in the Periodontium

A nucleophilic Ser residue at the active site of serine proteinases gives this class of enzyme its name. These proteinases play important roles in several biological functions, like clot formation and wound healing through the ability to activate PARs. The main PAR-activating proteinases found in the periodontal environment are neutrophil proteinase 3, thrombin, plasmin, trypsin, MMP-1, MMP-13, and gingipains (Table 1).

Neutrophil proteinase 3 is a multifunctional serine proteinase mainly located on the cell surface and in the azurophilic granules of neutrophils which are the predominant cell type in the periodontal pocket of chronic periodontitis and represent the first line of defense against infection. Interestingly, in inflammatory states, the intracellular proteinase 3 can be translocated to the cell surface, thus increasing the accessibility of proteinase 3 to bind to molecules such as PARs [34]. As neutrophil proteinase 3, elastase is a protease stored in the secretory granules which are released during the inflammatory process. These neutrophil proteinases differentially activate PARs 1 and 2 by a biased signaling mechanism that can both disarm the receptors from thrombin and trypsin activation and can cleave the receptors at distinct N-terminal residues to unmask different “noncanonical” receptor-activating tethered ligand sequences, triggering different signaling pathways from thrombin and trypsin [2, 35, 36]. In PAR3, neutrophil proteinase 3, elastase, and cathepsin G (another neutrophil proteinase) can cleave the receptor downstream from the canonical trypsin site, serving as a deactivating proteinase and also as a biased PAR2 agonist. Although the impact of these proteinases in PAR3 activation is uncertain, it is believed that they play a role in inflammatory diseases [35].

Thrombin is another endogenous serine proteinase that can be released from fibrin clot following gingival tissue injury or inflammation. In gingival tissues, thrombin has been suggested to play a role in the healing processes, since it is known that thrombin-rich and platelet-rich plasma has been successfully used for periodontal regenerative surgery. Recently, it has been suggested that several cell functions that regulate inflammation, healing, and fibrosis in the periodontium can be mediated through the activation of PARs by thrombin [15].

Plasmin is a serine proteinase which not only acts on fibrin degradation leading to clot dissolution but also activates MMPs, growth factors, and proteinase-activated receptors (PARs). Studies have shown that plasmin may activate different cell types, playing a role in the process of tissue remodeling, repair, and host defense [37–39]. In periodontium, Sulniute et al. [40] showed that plasmin plays an important role in preventing the development of chronic periodontitis in mice. In addition, a recent study suggested that plasmin may reduce lipopolysaccharide- (LPS-) induced inflammatory osteoclastogenesis through PAR1 activation [13]. Increased mast cell tryptase is found at the mucosal and subcutaneous connective tissue [41] and at the gingival crevicular fluid of patients with chronic periodontal diseases [42–45]. Holzhausen et al. [46] showed that the selective inhibition of tryptase with a compound named nafamostat mesilate leads to decreased gingival tissue granulocyte infiltration, decreased alveolar bone loss, and decreased PAR3 expression in the gingival tissue of rats subjected to experimental periodontitis, therefore suggesting that tryptase may play a role in the pathogenesis of chronic periodontal disease through PAR3 activation.

Interestingly, the zinc-dependent endopeptidases, MMP-1 and MMP-13, also have demonstrated the ability to activate PAR3. MMPs cleave PAR at noncanonical sites distinct from thrombin, generating unique tethered ligands which activate biased signaling pathways associated with thrombus initiation and thrombosis, atherosclerosis and restenosis, sepsis, angiogenesis, heart failure, and cancer. da Silva et al. [47]
Table 1: Potential activators of PARs in the periodontium.

| Protease | Protease-3 | Thrombin | Plasmin | Tryptase | MMP-1 & MMP-13 | Gingipains | Dentilisin | Aa protease |
|----------|------------|----------|---------|----------|----------------|------------|------------|------------|
| Origin   | Neutrophils| Fibrin clot| Fibrin clot| Mast cells| Monocytes/macrophages| Porphyromonas gingivalis| Treponema denticola| Aggregatibacter actinomycetemcomitans |
| Type     | Serine protease| Serine protease| Serine protease| Chymotrypsin-like protease| Collagenases| Cysteine proteases (i) Arginine (HRgpA and RgpB) (ii) Lysine (Kgp)| Chymotrypsin-like enzyme| Arginine and lysine proteases |
| PAR interaction | PAR<sub>2</sub> activation | PAR<sub>4</sub> activation | PAR<sub>4</sub> activation | PAR<sub>2</sub> activation | PAR<sub>4</sub> activation | PAR<sub>3</sub> activation | PAR<sub>3</sub> disarming | PAR<sub>3</sub> activation |

PAR: protease activated receptor; MMP: matrix metalloproteinase; Aa: Aggregatibacter actinomycetemcomitans.
demonstrated that increased MMP-13 levels were associated with an increased PAR1 expression at the gingival crevicular fluid of patients with chronic periodontitis after nonsurgical periodontal treatment.

In addition to host origin proteinases, exogenous serine proteinases originated by periodontopathic bacteria can also play a role in the innate response mediated by PARs. *Porphyromonas gingivalis*, for instance, produces and releases the cysteine proteinases, arginine-gingipain (HRGpA and RgpB) and lysine-gingipain (Kgp) which are strongly associated with periodontal breakdown and disruption of host defense. Some of the mechanisms played by gingipains are mediated by PARs 1 and 2, due to their potential to interact with host cell surface receptors modulating the innate response.

Other nonmammalian proteinases produced by periodontal pathogens have already been suggested to play a role on PAR function. Dentilisin, a chymotrypsin-like enzyme produced by *Treponema denticola*, is suggested to cause PAR disarming or inhibition to further activation [6]. Interestingly, a study by Euzebio Alves et al. [32] has demonstrated an inverse relationship between PAR expression and the expression of dentilisin in the periodontal sites of moderate chronic periodontitis patients. Another bacterial proteinase, an arginine- and lysine-specific proteinase produced by *Aggregatibacter actinomycetemcomitans*, was shown to induce interleukin (IL)-8 and intercellular adhesion molecule-1 (ICAM-1) expression in gingival epithelial cells through PAR2 activation [48]. It can be suggested that bacterial proteinases produced by other periodontal pathogens could also play a role on the activation or suppression of PAR function or expression.

Interestingly, the plasma contains serine proteinase inhibitors (serpins) that can regulate proteolytic events in tissues [2, 49]. The easy accessibility of the reactive site loops of serpins guarantees the rapid inhibition of specific host proteinases, but it also makes them easy targets for bacterial proteinases, which can specifically inactivate them. In fact, the ability to resist inhibition by serpins is also important in host defense evasion by bacterial pathogens. Accordingly, Euzebio Alves et al. [32] have demonstrated that elevated levels of gingipain and proteinase 3 and decreased levels of secretory leucocyte proteinase inhibitor (SLPI) were associated to PAR overexpression. SLPI is expressed by epithelial and immune cells where they play a role as an alarm proteinase inhibitor mediating anti-inflammatory and antimicrobial effects. In this study, decreased levels of SLPI were found in chronic periodontitis patients, whereas periodontal treatment led to its upregulation. The authors suggested that these results might be explained by the ability of the arginine-specific gingipains (Rgps) to degrade SLPI. Similarly, reduced SLPI levels and higher serine proteinase activities correlating with PAR2 overexpression were found in the gastric mucosa of *Helicobacter pylori*-infected individuals. This fact may be associated to the loss of host protective capacity and increase susceptibility to breakdown from chronic infection. These data reinforce the role played by *Porphyromonas gingivalis* on PAR2-mediated periodontal inflammation.

### 3. Biological Effects of PAR1 Activation in Periodontal Cells and Tissues

PAR1 involvement in periodontal tissue metabolism has been suggested by several in vitro studies which have shown expression of its receptor by the periodontal cells such as human gingival fibroblasts, gingival epithelial cells, periodontal ligament cells, osteoblasts, and monocytic cells and presence of its possible activators, thrombin, plasmin, MMPs, and gingipains, in the periodontal environment (Table 2).

The biological effects of PAR1 activation on the periodontium are still not well clarified. Some studies have shown that PAR1 activation has a tissue destructive profile, leading to the induction of proinflammatory mediators that regulate periodontal breakdown, while others highlighted its possible involvement with the repair of periodontal tissues [11, 12].

Uehara et al. [50] have showed that production of hepatocyte growth factor (HGF) by human gingival fibroblasts upon stimulation with gingipains occurred through PARs, specifically PAR1 and PAR2. HGF plays a role in wound healing, through its mitogenic activity to gingival epithelial cells, and enhances matrix metalloproteinases production, therefore playing a fundamental role in tissue remodeling. Moreover, HGF also stimulates blood vessel formation and promotes vascularization, a later process in wound healing.

In gingival fibroblasts, thrombin and a specific PAR1-activating peptide-induced proliferation through endothelin-1 (ET-1) are involved in drug-induced proliferation of gingival fibroblasts [14]. In this context, an in vitro study [15] demonstrated that thrombin and PAR1 agonist induced connective tissue growth factor (CTGF) synthesis and TGF-β1 activation in gingival fibroblasts. TGF-β1 and CTGF are proteins that regulate many biological effects, such as cell adhesion, migration, differentiation, proliferation, extracellular matrix production, angiogenesis, and wound healing. As well as ET-1, it is suggested that its overexpression may be involved in gingival overgrowth.

Moreover, Rohani et al. [16] showed that activation of PAR1 by thrombin in gingival epithelial cells leads to induction of chemokines which are important chemo-attractants for neutrophils and have a role in wound healing.

Thrombin exerts multiple effects upon osteoblasts including stimulating proliferation and inhibiting osteoblast differentiation and apoptosis. Some of these effects such as synthesis and secretion of growth factors and cytokines are believed to be mediated through PAR activation. In fact, Pagel et al. [51] demonstrated that thrombin produced TGF-β1, cyclooxygenase-2, tenasin C, fibroblast growth factors 1 and 2, connective tissue growth factor, and IL-6 expression in wild-type osteoblasts, but not in PAR1 knock-out mouse osteoblasts. In addition, PAR1-specific activating peptide and thrombin induced release of both prostaglandin E2 and IL-6 by osteoblasts, therefore suggesting the receptor participation in the earliest stages of bone healing.

The other evidence that links PAR1 action to bone metabolism comes from the fact that in periodontal ligament cells, PAR1 activation by thrombin induces the synthesis of
osteoprotegerin, which is one of the key molecules that regulate bone homeostasis and prevent osteoclastogenesis [12]. Corroborating with these findings, a recent study found that the activation of PAR1 in monocytic cells by plasmin diminished LPS-induced inflammatory osteoclastogenesis and bone resorption by inactivation of nuclear factor kappa beta (NF-kB) [13]. Conversely, Uehara et al. [17] showed that the gingipains Rgp and Kgp synergistically increase the secretion of proinflammatory cytokines such as IL-8 from human monocytic cells via PAR1, PAR2, and PAR3 in combination with Toll-like receptors or NOD agonists (pathogen-associated molecular pattern receptors). This study was the first one to report that gingipains stimulate the secretion of cytokines from monocytic cells through the activation of PARs with synergistic effects by pathogen-associated molecular patterns (PAMPs). In addition, Giacaman et al. [52] have showed that selective cleavage of PAR1 on oral epithelial cells by the gingipain Rgp upregulates expression of the proinflammatory cytokines IL-1α, IL-1β, IL-6, and tumor necrosis factor alpha (TNF-α).

Interestingly, gingipains-R (RgpB and HRgpA) were also shown to activate PAR2 in platelets leading to platelet aggregation [18]. This mechanism may explain the biological plausibility of the association between periodontitis and cardiovascular disease and deserves further clarification by future studies.

Taken together, the results from these in vitro studies show that PAR1 is associated with both proinflammatory and reparative processes in the periodontium. However, Wong et al. [53] found no difference between PAR1+/− and PAR1 knockout mice with regard to alveolar bone loss in a Porphyromonas gingivalis-induced periodontal disease model, indicating that this receptor does not play a pivotal role in the progression of experimental periodontitis. Most recently, it was shown by Spolidorio et al. [54] that parostatin, a 41-amino acid peptide released upon PAR1 activation, has potential anti-inflammatory effects since it decreases inflammatory cell infiltration, myeloperoxidase (MPO) activity, and proinflammatory mediators’ levels, including IL-1β, IL-6, and TNF-α in gingival tissues of rats subjected to experimental periodontal disease.

Furthermore, a recent study by da Silva et al. [47] has suggested the first clinical evidence of the association of PAR1 with periodontal repair. The authors demonstrated that PAR1 expression was downregulated in chronic periodontitis patients and inversely correlated to gingival crevicular fluid levels of IL-6, IL-8, TNF-α, IFN-γ, and MMP-2. In addition, periodontal therapy resulted in PAR1 overexpression by epithelial and immune cells from the gingival crevicular fluid, therefore suggesting the importance of PAR1 mediating the known anabolic actions of thrombin in the periodontium.

4. Biological Effects of PAR2 Activation in Periodontal Cells and Tissues

PAR2 acts as a “sensor” of bacterial and host proteinases and modulates host immune defense playing a role in the host alarm system [55, 56]. PAR2 has been localized in many cell types (Table 3) that can be found in periodontal tissues, including neutrophils, osteoblasts, oral epithelial cells, and human gingival fibroblasts [18, 21, 50, 57]. Gingipains from Porphyromonas gingivalis, neutrophil proteinase 3, and mast cell tryptase are the agonists that can possibly be found at the periodontal environment and that have already been studied for their ability to activate PAR2.

Gingipains have been shown to activate PAR3 in immunoinflammatory cells that play important roles in periodontal disease development. For instance, PAR3 activation by RgpB leads to neutrophil activation as indicated by increased intracellular calcium concentrations [57]. In addition, gingipains (Rgps and Kgp) may activate PARs (PAR1, PAR2, and PAR3) in monocytic cells increasing production of IL-6, IL-8, and monocyte chemoattractant protein (MCP)-1 [17]. Furthermore, Yun et al. [58] showed that RgpA activated the protease-activated receptors and induced T-cell activation. Taken together, these findings suggest that Porphyromonas gingivalis, through its gingipains, makes use of the host cell PAR2 to exacerbate inflammation during chronic periodontal disease.

One of the most important mechanical barriers that the bacteria encounter to invade the periodontium is the epithelial tissue. Besides the physical barrier, the epithelial tissues have also the ability to produce antimicrobial peptides such as the β-defensins (hBD). Interestingly, a study by Chung et al. [59] showed that gingipains may also play a protective

| Table 2: Biological effects of PAR1 activation in periodontal cells. |
|-------------------------------------------------|
| **PAR1** | Periodontal destruction | Periodontal repair/protection |
| Oral epithelial cells | → IL-1α, IL-1β, IL-6, TNFα [52] | → HGF [50] |
| | → CXCL 5 [16] | → endothelin-1 [14] |
| Gingival fibroblasts | → COX-2 [51] | → TGF-β [51] |
| | → IL-6 [51] | → FGF-1/FGF-2 [51] |
| | → PGE2 [51] | → CTFG [51] |
| Osteoblasts | → IL-8 [17] | → osteoprotegerin [12] |
| Periodontal ligament cells | | |
| Mononuclear cells | | |

PAR: protease-activated receptor; IL: interleukin; TNF: tumor necrosis factor; CXCL: C-X-C motif chemokine; COX: cyclooxygenase; PGE: prostaglandin E; HGF: hepatocyte growth factor; TGF: transforming growth factor; FGF: fibroblast growth factor; CTFG: connective tissue growth factor.
role by increasing hBD-2 expression in gingival epithelial cells partially through PAR2 receptor signaling pathway. In addition, Pereira et al. [60] have showed that in subjects with chronic periodontitis there are significantly higher levels of Porphyromonas gingivalis associated with increased salivary hBD-2 levels and gingival crevicular fluid PAR2 mRNA expression than in healthy subjects and that periodontal treatment decreases both hBD-2 levels and PAR2 expression. On the other hand, gingipains have also been shown to activate PAR2 on oral epithelial cells leading to the production of proinflammatory mediators, such as IL-6 [18] and IL-8 [17] that could result in periodontal tissue breakdown. Moreover, Giacaman et al. [52] suggested that gingipains Rgp and Kgp may cleave and activate PAR2 in oral keratinocytes upregulating the expression of IL-1α, IL-1β, IL-6, and TNF-α. Furthermore, a recent study by Tada et al. [61] found that the expression of IL-33, a cytokine that augments Th2 cytokine-mediated inflammatory responses, is increased during Porphyromonas gingivalis infection in human gingival epithelial cells via PAR2 through gingipain-dependent activation.

As the bacteria challenge increases, an enhanced permeability of the small blood vessels of the subgingival plexus occurs resulting in an increased neutrophil migration through the junctional epithelium and into the gingival sulcus. Interestingly, activated neutrophils may secrete a protease (neutrophil proteinase 3) which was shown to activate human oral epithelial cells through PAR2, inducing IL-8 and monococyte chemoattractant protein-1 production [17].

Increased levels of proinflammatory mediators and pathogenic bacteria in the soft tissues may lead to the disruption of the epithelial tissue, which in turn facilitates the access of bacteria and their products to the subepithelial connective tissue. The exposure of the residing periodontal connective tissue cells to the bacterial agents may transform them into major participants in the pathophysiological process of periodontal tissue destruction. The dominant cell type in periodontal connective tissue is the fibroblast. Interestingly, Uehara et al. [50] demonstrated that human gingival fibroblasts express PAR2 and that its activation by a synthetic PAR2 agonist peptide (SLIGRL) induces the production of IL-8 which has the ability to selectively stimulate MMP activity, responsible for collagen destruction within periodontitis lesions. Porphyromonas gingivalis may exacerbate this process since it was demonstrated that gingipains upregulate PAR2 gene expression in human gingival fibroblasts [62].

Abraham et al. [21] demonstrated that PAR2 is expressed by osteoblasts and that its activation by a specific synthetic peptide did not show any effect on osteoblast proliferation or differentiation. In addition, in this study, osteoblast-mediated osteoclast bone resorption was also not stimulated by PAR2 activation. Furthermore, Smith et al. [63] showed that PAR2 activation inhibits expression of receptor activator of nuclear factor kappa-B ligand (RANKL) and suppressed the RANKL: osteoprotegerin ratio in osteoblasts. However, a study by Amiable et al. [64] showed that PAR2 activation in osteoarthritis subchondral bone osteoblasts induced a significant upregulation of RANKL and significantly enhanced bone resorptive activity. Interestingly, these findings on the resorptive properties played by PAR2 in osteoblasts are in agreement with data reporting the involvement of PAR2 activity in periodontitis [6, 30–33, 65].

Accordingly, it has been shown that a selective PAR2 agonist (SLIGRL) causes periodontitis in rats through a mechanism involving prostaglandin release and MMP activation [65] and that PAR2-knockout mice infected with Porphyromonas gingivalis have decreased levels of proinflammatory mediators, such as prostaglandin E2, interferon-gamma, IL-1beta, and IL-6, and less alveolar bone loss when compared to wild-type animals [6].

Wong et al. [53] also have shown that less alveolar bone resorption occurred in PAR2-knockout mice. In addition, they showed that T-cells from Porphyromonas gingivalis-infected PAR2−/− mice proliferated less in response to antigen than those from wild-type mice and that T-cells from infected or antigen-immunized PAR2−/− null mice had a significantly different Th1/Th2 profile from wild-type cells such as decreased gamma interferon, ILs (IL-2, IL-3, and IL-17), granulocyte-macrophage colony-stimulating factor, and TNF-alpha than wild-type controls. The absence of PAR2 therefore appears to substantially decrease T-cell activation and the Th1/Th2 regulatory response. In this study [53], increased numbers of mast cells in the maxillary tissue of infected PAR2−/− mice were also shown, indicating that PAR2 may also have a role in mast cell differentiation or infiltration into tissues. Thus, activation of PAR2 expressed by mast cells by the arginine-specific gingipains from Porphyromonas gingivalis may lead to the release of inflammatory mediators that are pivotal to early inflammatory response in chronic periodontitis. It has been shown that activation of PAR2 leads to degranulation of mast cells, causing the release of proinflammatory compounds that kill

| PAR2          | Periodontal destruction                                 | Periodontal repair/protection               |
|---------------|--------------------------------------------------------|--------------------------------------------|
| Epithelial cells | ↑ IL-1α, IL-1β, IL-6, IL-8, TNFα [4, 47]               | ↑ β-defensin 2 [59]                        |
| Fibroblasts   | ↑ MCP-1 [17]                                           | ↓ RANKL [63]                              |
| Osteoblasts   | ↑ RANKL [64]                                           | ↓ RANKL: osteoprotegerin ratio [63]        |
| Monocytic cells | ↑ IL-6, IL-8, MCP-1 [17]                               |                                           |

IL: interleukin; MCP: monocyte chemoattractant protein; RANKL: receptor activator of nuclear factor kappa-B ligand.
pathogens and upregulate the immune responses. In addition, trypsin, released from the granules of mast cells upon degranulation, may also activate PAR₂, and therefore, these cells could play a role in periodontitis by causing the activation of the receptor on other cells in the periodontal tissues. Thus, the regulation of such proinflammatory mechanisms in T-cells and mast cells by PAR₂ suggests a pivotal role in the pathogenesis of the disease (Table 4).

In the gingival crevicular fluid from patients with periodontal disease, there are high levels of proteolytic activity characterized by a mixture of endogenous and exogenous proteinases which may mediate degradation of connective tissue [66]. Among these hydrolytic enzymes in the inflamed periodontal environment, neutrophil proteinase 3, mast cell trypsin, and gingipains have been isolated and are known to activate PAR₂. In fact, high levels of proteolytic activity derived from both Porphyromonas gingivalis and neutrophils are expected to be found in the periodontal pocket of chronic periodontitis, since they are, respectively, the major periodontal pathogen and the predominant cells (approximately 90%).

PAR₂ has been shown to be expressed by cellular elements found in gingival crevicular fluid, which may include epithelial cells, and leukocytes even in clinically healthy human gingival sulci [30]. In addition, PAR₂ expression is upregulated in chronic periodontitis patients compared to that in healthy controls (Table 5). Interestingly, PAR₂ upregulation in the inflamed periodontium is associated with an elevated gingival crevicular fluid trypsin-like activity, probably due to the increased prevalence of Porphyromonas gingivalis, and expression of neutrophil proteinase 3 [30].

Importantly, proteinase 3 has been shown to activate oral epithelial cells through PAR₂, leading to the production of IL-8 and monocyte chemoattractant protein-1 [17]. These findings clearly suggest that proteinase 3 actively participates in PAR₂-mediated inflammation at periodontal sites.

PAR₂ activation results in the synthesis of proinflammatory mediators including IL-6, IL-8, IL-1, IFN-γ, PGE₂, and MMP-9 [6, 67, 68] and activates signaling pathways such as those involving mitogen-activated protein kinase and nuclear factor-κB, which potentiates inflammatory responses [69]. Interestingly, proinflammatory mediators such as TNF-alpha and IL1-beta are reported to increase PAR₂ expression [30]. Accordingly, an increased PAR₂ expression has been demonstrated in deeper periodontal pockets compared to the expression of the receptor in shallower pockets, and it was associated with significant increased levels of proinflammatory mediators [30]. In addition, periodontal treatment statistically reduces PAR₂ expression [30, 32]. Furthermore, Fagundes et al. [31] demonstrated that the presence of Porphyromonas gingivalis is associated with an elevated expression of PAR₂ in human chronic periodontitis, thus suggesting that Porphyromonas gingivalis may disturb the host inflammatory responses not only by regulating PAR₂ function but also by enhancing its genetic expression. Taken together, these findings clearly suggest that PAR₂ overexpression is an essential element in inflammation severity.

Another study by Euzebio Alves et al. [32] showed that PAR₂-positive staining in gingival crevicular fluid cells was reflective of tissue destruction, and its overexpression was positively associated to inflammatory clinical parameters and to the levels of the proinflammatory mediators IL-6, IL-8, TNF-alpha, MMP-2, MMP-8, hepatocyte growth factor, and vascular endothelial growth factor (VEGF). Another interesting finding from this study was that periodontally healthy sites from chronic periodontitis individuals showed a diminished expression of PAR₂ mRNA and PAR₂ protein level, therefore suggesting that PAR₂ periodontal expression is influenced by the presence of infection and not merely a constitutive characteristic that may favor periodontal inflammation.

5. Specific Synthetic Agonists

Selective synthetic peptides, corresponding to the tethered ligand sequences, are able to activate selectively the receptors through direct binding to the body of the receptor without the need of proteolysis [22]. With the exception of PAR₅, all the other receptors have their selective agonist peptides. PAR₁, PAR₂, and PAR₄ can be nonenzymatically and selectively activated by TFFRR-NH₂, SLIGRL-NH₂, and GYPGQVNH₂, respectively [1, 2]. Since their discovery, selective PAR agonists have been used in order to assess the specific impact of PAR₁, PAR₂, and PAR₄ signaling.

Noteworthy, earlier literature in many instances used the “TRAP” peptide (SFLLRN) to activate “PAR,” not realizing that the peptide also coactivates PAR₂ [36]. Thus, the earlier use of the “TRAP” peptide may have generated results that reflect the coactivation of both PARs 1 and 2. Furthermore, the PAR₂-activating peptide (SLIGRL-NH₂) can in some settings cross-react with the MAS receptor, whereas the use of a more potent 2-furoyl-LIGRLO-amide can prevent this issue [36].

6. Recent PAR Antagonists

The newest PAR₂ antagonist (Vorapaxar) has been used for the treatment of cardiovascular diseases. Vorapaxar acts by blocking the docking of the tethered ligand sequence preventing PAR₂ activation, hence platelet aggregation [10]. Regarding PAR₁ blockage, the antagonist GB88 can block PAR₁ activation by trypsin as well as PAR-activating peptide. GB88 has been shown to inhibit PAR₂-induced proinflammatory cytokine release and attenuate inflammation in a rat model of colitis [10]. However, until now, none of these antagonists were studied in periodontics.

7. PARs: Drug Targets in Inflammation

Therapies focusing on the inhibition of proteinases or, more specifically, the use of PAR antagonists may constitute an important approach for the modulation of an infectious pathology such as periodontal inflammatory disease.

According to Yun et al. [58], PAR₂ blockage with the use of antagonists might promote adverse high proteolytic activities in the gingival crevicular fluid. Thus, it seems that the
| Author(s)/year | In vivo model | PAR | Experimental groups | Biological effect(s) | Mechanism(s) involved |
|----------------|--------------|-----|---------------------|----------------------|-----------------------|
| Holzhausen et al. [65] | Male Wistar rats subjected to ligature-induced periodontitis (right mandibular first molar) | PAR2 | (i) Ligature + saline, n = 32  
(ii) Ligature + SLIGRL-NH₂ (agonist peptide), n = 32  
(iii) Ligature + LRGILS-NH₂ (control peptide), n = 32  
(iv) Sham + saline, n = 32  
(v) Sham + SLIGRL-NH₂, n = 32  
(vi) Sham + LRGILS-NH₂, n = 32 | PAR2 agonist induced alveolar bone loss and granulocyte infiltration and exacerbated ligature-induced periodontitis. | Upregulation of COX-1, COX-2, MMP-2, and MMP-9. |
| Holzhausen et al. [6] | PAR2-deficient mice subjected to *P. gingivalis* oral infection | PAR2 | (i) PAR2⁻/⁻ mice + *P. gingivalis* oral infection, n = 20 | PAR2⁻/⁻ mice showed less alveolar bone loss compared to WT mice. | PAR2 activation in the presence of *P. gingivalis* infection increased inflammatory cell infiltration, prostaglandin-E₂, IFN-γ, IL-6, and IL-1β levels. |
| Wong et al. [53] | PAR1-deficient mice subjected to *P. gingivalis* oral infection | PAR1 | (i) PAR1⁻/⁻ mice + *P. gingivalis* oral infection, n = 24  
(ii) Control group: daily i.p. administration of saline, n = 20  
(iii) Ligature group: ligature placement and daily i.p. administration of saline, n = 20 | No difference between PAR1⁻/⁻ and PAR1 WT mice with regard to the exposed root surface. | PAR2-deficient mice showed decreased infiltration of mast cells in the periodontal tissues and impaired T-cell immune responses (decreased activation and Th1/inflammatory response). |
| Holzhausen et al. [46] | Male Wistar rats subjected to ligature-induced periodontitis (right mandibular first molar) | PAR2 | (iii) Nafamostat mesilate (NM) group: NM (0.1 mg/kg/day, i.p.) a potent tryptase inhibitor, n = 20  
(iv) NM + ligature group: ligature and daily i.p. NM (0.1 mg/kg/day), n = 20 | Tryptase inhibition decreased alveolar bone loss, MPO, and total proteolytic activity in animals subjected to ligature-induced periodontitis. | Tryptase inhibition led to a 1.6-fold decrease in gingival PAR2 expression. |
| Author(s)/year | In vivo model | PAR | Experimental groups | Biological effect(s) | Mechanism(s) involved |
|---------------|---------------|-----|---------------------|----------------------|----------------------|
| Spolidorio et al. [54] | Male Wistar rats subjected to ligature-induced periodontitis (upper second molars) | PAR₁ | (i) Ligature + intraoral 3 μg parstatin, n = 16 (ii) Ligature + intraoral PBS, n = 16 (iii) Sham, n = 8 | Parstatin (peptide released upon PAR₁ activation) prevented periodontal tissue breakdown. | Parstatin suppressed inflammatory cell infiltration and decreased MPO, IL-1β, TNF-α, and IL-6. |
| Castro et al. [33] | Male Wistar rats subjected to ligature-induced periodontitis (mandibular first molars) | PAR₂ | (i) No ligature and no treatment, n = 20 (ii) Ligature + placebo (0.9% NaCl solution), n = 20 (iii) Ligature + 5 mg subantimicrobial dose of doxycycline (SDD) by daily gavage, n = 20 | SDD downregulated alveolar bone loss. | Downregulation of PAR₂, IL-17, IL-1β, and TNF-α. |

PAR: protease-activated receptor; COX: cyclooxygenase; MMP: matrix metalloproteinase; *P. gingivalis*: Porphyromonas gingivalis; WT: wild-type mice; IL: interleukin; IFN-γ: interferon gamma; MPO: myeloperoxidase; PBS: phosphate-buffered saline; TNF: tumor necrosis factor.
potential side effects that the concept of PAR2 blockade encounters do not seem to overcome the beneficial aspects for the treatment of periodontal inflammation.

At a certain point in the inflammatory process, PAR 1 and 2 blockages may be necessary to prevent increased inflammation, whereas at later time points, PAR activation may be required to aid resolution. Further, the use of specific proteinase inhibitors, rather than PARs antagonists, may result in a “dual” blockage inhibiting both the degradation of host molecules and activation of PARs. Golub et al. [70] found that tetracyclines can inhibit tissue collagenolytic activity in vivo, in vitro, and periodontal pockets presented by subjects with and without diabetes. Castro et al. [33] found that administration of a subantimicrobial dose of doxycycline (SDD) in a rat periodontitis model may result in PAR2 modulation through a dual mode, downregulating its gene expression and decreasing its posterior activation by proteinases. Doxycycline in a subantimicrobial dose is able to inhibit the activity of MMPs and thus reduce the degradation of collagen, fibronectin, and elastin in the periodontal tissues [71], and its clinical use in the modulation of the immuno-inflammatory host response as coadjuvant to periodontal conventional therapy is approved by the Food and Drug Administration since 1998. Moreover, in periodontal inflammation, the inhibition of MMPs by drugs from the tetracycline family may not only attenuate the activation of PARs by MMPs but also can prevent extracellular matrix remodeling which can sequester cell-regulating polypeptide that in turn can act together with the PAR-promoting fibrosis [2]. However, additional studies are necessary to confirm the clinical benefits of tetracycline family and other highly specific inhibitors on PAR-mediated periodontal inflammation.

### 8. Concluding Remarks

PARs together with Toll-like receptors and NOD-like receptors are pattern recognition receptors that contribute to innate immunity. A new paradigm in microbial pathogenicity has been established in which bacterial proteinases manipulate host cell functions through PAR activation. An uncontrolled PAR activation will certainly result in a disruptive local inflammatory response, which can benefit the periodontal microbial community.

The in vitro studies described here highlight the differential actions of PARs on periodontal cells, suggesting that PARs, like other components of the innate immunity, act as a double-edged sword with both protective and destructive responses. However, in periodontal tissues, PAR2 seems to be upregulated during inflammation, where it is believed to be activated by bacterial and host proteinases, whereas PAR1 is upregulated during periodontal tissue repair. This counterregulation of PARs actions was also demonstrated by Xue et al. [72] in rheumatoid arthritis synovial fibroblasts, where PAR activation was associated with an elevated TNF-alpha release and PAR1 activation prevented the release of proinflammatory cytokines. Interestingly, da Silva et al. [47] showed that PAR1 overexpression after periodontal treatment was inversely correlated to PAR2 expression in gingival crevicular fluid levels of IL-6, IL-8, TNF-alpha, IFN-gamma, and MMP.

### Table 5: Human studies on PAR1 and PAR2 activation associated with periodontal tissue metabolism.

| Groups | Main findings |
|--------|---------------|
| Holzhausen et al. [30] | (i) Controls: 40 subjects<br>(ii) Chronic periodontitis with moderate destruction<br>\(3 < \text{PPD} \leq 6 \text{ mm}; \text{CAL} \leq 4 \text{ mm}, n = 40\)<br>(iii) Chronic periodontitis with advanced destruction<br>\(\text{PPD} > 6 \text{ mm}; \text{CAL} > 4 \text{ mm}, n = 40\) | (i) Chronic periodontitis patients showed higher PAR2 mRNA expression and increased levels of IL-1α, IL-6, IL-8, TNF-α, total proteolytic activity, *P. gingivalis* prevalence, and proteinase 3 mRNA expression compared to controls.<br>(ii) Periodontal treatment decreased PAR2 mRNA expression. |
| Fagundes et al. [31] | (i) Moderate chronic periodontitis<br>\(3 < \text{PPD} \leq 6 \text{ mm}; 3 < \text{CAL} \leq 6 \text{ mm}, n = 35\) | *P. gingivalis* presence was associated with the following:<br>(i) higher levels of IL-1α, IL-6, and TNF-α,<br>(ii) higher proteolytic activity,<br>(iii) higher PAR2 mRNA expression. |
| Euzebio Alves et al. [32] | (i) Controls: 31 subjects<br>(ii) Moderate chronic periodontitis<br>\(3 < \text{PPD} \leq 6 \text{ mm}; \text{CAL} \leq 4 \text{ mm}, n = 31\) | Chronic periodontitis patients showed overexpression of PAR1, IL-6, IL-8, TNF-α, MMP-2, MMP-8, HGF, VEGF, gingipain, and proteinase 3 and decreased levels of dentilisin, SLPI, and elafin. Periodontal treatment decreased PAR2 expression. |
| da Silva et al. [47] | (i) Controls: 37 subjects<br>(ii) Moderate chronic periodontitis<br>\(3 < \text{PPD} \leq 6 \text{ mm}; \text{CAL} \leq 4 \text{ mm}, n = 38\) | Periodontal treatment resulted in PAR1 overexpression, which was inversely correlated with PAR2 expression and gingival crevicular fluid levels of IL-6, IL-8, TNF-α, IFN-γ, and MMP. |

PAR: protease activated receptor; IL: interleukin; *P. gingivalis*: Porphyromonas gingivalis; PPD: probing pocket depth; CAL: clinical attachment level; TNF: tumor necrosis factor; P3: neutrophil serine protease 3; MMP: matrix metalloproteinase; HGF: hepatocyte growth factor; VEGF: vascular endothelial growth factor; SLPI: secretory leukocyte protease inhibitor; GCF: gingival crevicular fluid; IFN-γ: interferon gamma.
Conflicts of Interest

The authors declare that they have no conflict of interests.

Acknowledgments

This work was supported by grants from the Sao Paulo Research Foundation (FAPESP Grant nos. 2015/07396-2 and 2015/11587-8).

References

[1] V. S. Ossovskaya and N. W. Bunnett, "Protease-activated receptors: contribution to physiology and disease," *Physiological Reviews*, vol. 84, no. 2, pp. 579–621, 2004.

[2] R. Ramachandran, C. Altier, K. Oikonomopoulou, and M. D. Hollenberg, "Proteinases, their extracellular targets, and inflammatory signaling," *Pharmacological Reviews*, vol. 68, no. 4, pp. 1110–1142, 2016.

[3] N. Vergnolle, J. L. Wallace, N. W. Bunnett, and M. D. Hollenberg, "Protease-activated receptors in inflammation, neuronal signaling and pain," *Trends in Pharmacological Sciences*, vol. 22, no. 3, pp. 146–152, 2001.

[4] A. Lourbakos, J. Potempa, J. Travis et al., "Arginine-specific protease from *Porphyromonas gingivalis* activates protease-activated receptors on human oral epithelial cells and induces interleukin-6 secretion," *Infection and Immunity*, vol. 69, no. 8, pp. 5121–5130, 2001.

[5] M. Holzhausen, L. C. Spolidorio, and N. Vergnolle, "Role of protease-activated receptor-2 in inflammation, and its possible implications as a putative mediator of periodontitis," *Memorias do Instituto Oswaldo Cruz*, vol. 100, Supplement 1, pp. 177–180, 2005.

[6] M. Holzhausen, L. C. Spolidorio, R. P. Ellen et al., "Protease-activated receptor-2 activation: a major role in the pathogenesis of *Porphyromonas gingivalis* infection," *American Journal of Pathology*, vol. 168, no. 4, pp. 1189–1199, 2006.

[7] O. Déry, C. U. Corvera, M. Steinhofer, and N. W. Bunnett, "Protease-activated receptors: novel mechanisms of signaling by serine proteases," *American Journal of Physiology*, vol. 274, no. 6 pt 1, pp. 1429–1452, 1998.

[8] S. R. Coughlin, "Thrombin signalling and protease-activated receptors," *Nature*, vol. 407, no. 6801, pp. 258–264, 2000.

[9] P. J. O’Brien, M. Molino, M. Kahn, and L. F. Brass, "Protease activated receptors: theme and variations," *Oncogene*, vol. 20, no. 13, pp. 1570–1581, 2001.

[10] R. Ramachandran, F. Noorbakhsh, K. Defea, and M. D. Hollenberg, "Targeting protease-activated receptors: therapeutic potential and challenges," *Nature Reviews Drug Discovery*, vol. 11, no. 1, pp. 69–86, 2012.

[11] S. J. Song, C. N. Pagel, T. M. Campbell, R. N. Pike, and E. J. Mackie, "The role of protease-activated receptor-1 in bone healing," *American Journal of Pathology*, vol. 166, no. 3, pp. 857–868, 2005.

[12] U. Arayatrakoolkit, P. Pavasant, and T. Yongschatrakul, "Thrombin induces osteoprotegerin synthesis via phosphatidylinositol 3′-kinase/mammalian target of rapamycin pathway in human periodontal ligament cells," *Journal of Periodontal Research*, vol. 43, no. 5, pp. 537–543, 2008.

[13] Y. Kanno, A. Ishisaki, E. Kawashita, H. Kuretake, K. Ikeda, and O. Matsuo, "uPA attenuated LPS-induced inflammatory osteoclastogenesis through the plasin/PAR-1/Ca(2+)/CaMKK/AMPK axis," *International Journal of Biological Sciences*, vol. 12, no. 1, pp. 63–71, 2016.

[14] N. Ohuchi, K. Hayashi, K. Iwamoto et al., "Thrombin-stimulated proliferation is mediated by endothelin-1 in cultured rat gingival fibroblasts," *Fundamental & Clinical Pharmacology*, vol. 24, no. 4, pp. 501–508, 2010.

[15] W. H. Yang, Y. T. Deng, Y. P. Hsieh, K. J. Wu, and M. Y. Kuo, "Thrombin activates latent TGFβ1 via integrin αvβ3 in gingival fibroblasts," *Journal of Dental Research*, vol. 95, no. 8, pp. 939–945, 2016.

[16] M. G. Rohani, R. P. Beyer, B. M. Hacker, H. Domnisch, B. A. Dale, and W. O. Chung, "Modulation of expression of innate immunity markers CXCL5/ENA-78 and CCL20/MIP3alpha by protease-activated receptors (PARs) in human gingival epithelial cells," *Innate Immunity*, vol. 16, no. 2, pp. 104–114, 2010.

[17] A. Uehara, T. Imanura, J. Potempa, J. Travis, and H. Takada, "Gingipains from *Porphyromonas gingivalis* synergistically induce the production of proinflammatory cytokines through protease-activated receptors with Toll-like receptor and NOD1/2 ligands in human mononcyt cells," *Cellular Microbiology*, vol. 10, no. 5, pp. 1181–1189, 2008.

[18] A. Lourbakos, Y. P. Yuan, A. L. Jenkins et al., "Activation of protease-activated receptors by gingipains from *Porphyromonas gingivalis* leads to platelet aggregation: a new trait in microbial pathogenicity," *Blood*, vol. 97, no. 12, pp. 3790–3797, 2001.

[19] S. K. Bohn, W. Kong, D. Bromme et al., "Molecular cloning, expression and potential functions of the human protease-activated receptor-2," *Biochemical Journal*, vol. 314, no. Pt 3, pp. 1009–1016, 1996.

[20] S. Nystedt, V. Ramakrishnan, and J. Sundelin, "The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells. Comparison with the thrombin receptor," *The Journal of Biological Chemistry*, vol. 271, no. 25, pp. 14910–14915, 1996.

[21] L. A. Abraham, C. Chinni, A. L. Jenkins et al., "Expression of protease-activated receptor-2 by osteoblasts," *Bone*, vol. 26, no. 1, pp. 7–14, 2000.

[22] T. M. Cocks and J. D. Moffatt, "Protease-activated receptors: sentries for inflammation?" *Trends in Pharmacological Sciences*, vol. 21, no. 3, pp. 103–108, 2000.

[23] N. Vergnolle, N. W. Bunnett, K. A. Sharkey et al., "Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway," *Nature Medicine*, vol. 7, no. 7, pp. 821–826, 2001.

[24] N. Cenac, A. M. Coelho, C. Nguyen et al., "Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2," *American Journal of Pathology*, vol. 161, no. 5, pp. 1903–1915, 2002.

[25] S. R. Coughlin and E. Camerer, "PArticipation in inflammation," *Journal of Clinical Investigation*, vol. 111, no. 1, pp. 25–27, 2003.

[26] A. M. Coelho, N. Vergnolle, B. Guiard, J. Fioramonti, and L. Bueno, "Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats," *Gastroenterology*, vol. 122, no. 4, pp. 1035–1047, 2002.

[27] F. Schmidlin, S. Armadesi, K. Dabbagh et al., "Protease-activated receptor 2 mediates eosiophil infiltration and hyperreactivity in allergic inflammation of the airway," *Journal of Immunology*, vol. 169, no. 9, pp. 5315–5321, 2002.
[28] W. R. Ferrell, J. C. Lockhart, E. B. Kelso et al., “Essential role for proteinase-activated receptor-2 in arthritis,” Journal of Clinical Investigation, vol. 111, no. 1, pp. 35–41, 2003.

[29] J. R. Lindner, M. L. Kahn, S. R. Coughlin et al., “Delayed onset of inflammation in protease-activated receptor-2-deficient mice,” Journal of Immunology, vol. 165, no. 11, pp. 6504–6510, 2000.

[30] M. Holzhausen, J. R. Cortelli, V. A. da Silva, G. N. Franco, S. C. Cortelli, and N. Vergnolle, “Protease-activated receptor-2 (PAR(2)) in human periodontitis,” Journal of Dental Research, vol. 89, no. 9, pp. 948–953, 2010.

[31] J. A. Fagundes, L. D. Monoo, V. T. Euzébio Alves et al., “Porphyromonas gingivalis is associated with protease-activated receptor-2 upregulation in chronic periodontitis,” Journal of Periodontology, vol. 82, no. 11, pp. 1596–1601, 2011.

[32] V. T. Euzébio Alves, H. A. Bueno da Silva, B. N. de França et al., “Periodontal treatment downregulates protease-activated receptor 2 in human gingival crevicular fluid cells,” Infection and Immunity, vol. 81, no. 12, pp. 4399–4407, 2013.

[33] M. L. Castro, G. C. Franco, L. S. Branco-de-Almeida et al., “Downregulation of protease-activated receptor-2, interleukin-17, and other proinflammatory genes by subantimicrobial doxycline dose in a rat periodontitis model,” Journal of Periodontology, vol. 87, no. 2, pp. 203–210, 2016.

[34] E. Cernok, M. Ernst, W. Schmitt, D. F. Bainton, and W. L. Gross, “Activated neutrophils express proteasome 3 on their plasma membrane in vitro and in vivo,” Clinical & Experimental Immunology, vol. 95, no. 2, pp. 244–250, 1994.

[35] P. Zhao, M. Metcalfe, and N. W. Bunnett, “Biased signaling of protease-activated receptors,” Frontiers in Endocrinology (Lausanne), vol. 5, p. 67, 2014.

[36] M. D. Hollenberg, K. Mihara, D. Polley et al., “Biased signaling and protease-activated receptors (PARs): targeting inflammatory disease,” British Journal of Pharmacology, vol. 171, no. 5, pp. 1180–1194, 2014.

[37] J. Romer, T. H. Bugge, C. Fyke et al., “Impaired wound healing in mice with a disrupted plasminogen gene,” Nature Medicine, vol. 2, no. 3, pp. 287–292, 1996.

[38] V. A. Ploplis, E. L. French, P. Carmeliet, D. Collen, and E. F. Plow, “Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice,” Blood, vol. 91, no. 6, pp. 2005–2009, 1998.

[39] D. Collen, “Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling,” Hema- tology / the Education Program of the American Society of Hema tology. American Society of Hematology. Education Program, vol. 2001, no. 1, pp. 1–91, 2001.

[40] R. Sulniute, T. Lindh, M. Wilczynska, J. Li, and T. Ny, “Plasmin is essential in preventing periodontitis in mice,” American Journal of Pathology, vol. 179, no. 2, pp. 819–828, 2011.

[41] S. Stevensvoll, K. Helgeland, and K. Schenck, “Mast cells—a role in periodontal diseases?” Journal of Clinical Periodontology, vol. 31, no. 6, pp. 413–419, 2004.

[42] B. M. Eley and S. W. Cox, “Cathepsin B/L-, elastase-, tryptase-, trypsin- and dipeptidyl peptidase IV-like activities in gingival crevicular fluid: a comparison of levels before and after periodontal surgery in chronic periodontitis patients,” Journal of Periodontology, vol. 63, no. 5, pp. 412–417, 1992.

[43] S. W. Cox and B. M. Eley, “Cathepsin B/L-, elastase-, tryptase-, trypsin- and dipeptidyl peptidase IV-like activities in gingival crevicular fluid. A comparison of levels before and after basic periodontal treatment of chronic periodontitis patients,” Journal of Clinical Periodontology, vol. 19, no. 5, pp. 333–339, 1992.

[44] B. M. Eley and S. W. Cox, “Correlation of gingival crevicular fluid proteases with clinical and radiological measurements of periodontal attachment loss,” Journal of Dentistry, vol. 20, no. 2, pp. 90–99, 1992.

[45] B. M. Eley and S. W. Cox, “Cathepsin B/L-, elastase-, tryptase-, trypsin- and dipeptidyl peptidase IV-like activities in gingival crevicular fluid: correlation with clinical parameters in untreated chronic periodontitis patients,” Journal of Periodontal Research, vol. 27, no. 1, pp. 62–69, 1992.

[46] M. Holzhausen, R. D. Balejo, G. M. Lara, S. C. Cortelli, W. A. Saad, and J. R. Cortelli, “Nafamostat mesilate, a potent tryptase inhibitor, modulates periodontitis in rats,” Clinical Oral Investigation, vol. 15, no. 6, pp. 967–973, 2011.

[47] H. A. da Silva, V. T. Euzébio Alves, L. C. Spolidório et al., “Expression of protease activated receptor-1 in chronic periodontitis,” Journal of Periodontology, vol. 85, no. 12, pp. 1763–1769, 2014.

[48] T. Shimada, N. Sugano, K. Ikeda, K. Shimada, T. Iizuka, and K. Ito, “Protease-activated receptor 2 mediates interleukin-8 and intercellular adhesion molecule-1 expression in response to Aggregatibacter actinomycetemcomitans,” Oral Microbiology and Immunology, vol. 24, no. 4, pp. 285–291, 2009.

[49] J. Travis and J. Potempa, “Bacterial proteases as targets for the development of second-generation antibiotics,” Biochimica et Biophysica Acta, vol. 1477, no. 1-2, pp. 35–50, 2000.

[50] A. Uehara, K. Muramoto, T. Imamura et al., “Arginine-specific gingipains from Porphyromonas gingivalis stimulate production of hepatocyte growth factor (scatter factor) through protease-activated receptors in human gingival fibroblasts in culture,” Journal of Immunology, vol. 175, no. 9, pp. 6076–6084, 2005.

[51] C. N. Pagel, S. J. Song, L. H. Loh et al., “Thrombin-stimulated growth factor and cytokine expression in osteoblasts is mediated by protease-activated receptor-1 and prostanoids,” Bone, vol. 44, no. 5, pp. 813–821, 2009.

[52] R. A. Giacaman, A. C. Asrani, K. F. Ross, and M. C. Herzberg, “Cleavage of protease-activated receptors on an immortalized oral epithelial cell line by Porphyromonas gingivalis gingipains,” Microbiology, vol. 155, no. 10, pp. 3238–3246, 2009.

[53] D. M. Wong, V. Tam, R. Lam et al., “Protease-activated receptor 2 has pivotal roles in cellular mechanisms involved in experimental periodontitis,” Infection and Immunity, vol. 78, no. 2, pp. 629–638, 2010.

[54] L. C. Spolidorio, P. D. Lucas, J. P. Steffens et al., “Impact of parstatin on experimental periodontal disease and repair in rats,” Journal of Periodontology, vol. 85, no. 9, pp. 1266–1274, 2014.

[55] N. Vergnolle, “Protease-activated receptors as drug targets in inflammation and pain,” Pharmacology & Therapeutics, vol. 123, no. 3, pp. 292–309, 2009.

[56] V. Shpacovitch, M. Feld, N. W. Bunnett, and M. Steinhoff, “Protease-activated receptors: novel PARtner in innate immunity,” Trends in Immunology, vol. 28, no. 12, pp. 541–550, 2007.

[57] A. Lourbakos, C. Chinni, P. Thompson et al., “Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis,” FEBS Letters, vol. 435, no. 1, pp. 45–48, 1998.
[58] L. W. Yun, A. A. Decarlo, and N. Hunter, "Blockade of protease-activated receptors on T cells correlates with altered proteolysis of CD27 by gingipains of Porphyromonas gingivalis," *Clinical & Experimental Immunology*, vol. 150, no. 2, pp. 217–229, 2007.

[59] W. O. Chung, S. R. Hansen, D. Rao, and B. A. Dale, "Protease-activated receptor signaling increases epithelial antimicrobial peptide expression," *Journal of Immunology*, vol. 173, no. 8, pp. 5165–5170, 2004.

[60] A. L. Pereira, M. Holzhausen, G. C. Franco, S. C. Cortelli, and J. R. Cortelli, "Human β-defensin 2 and protease activated receptor-2 expression in patients with chronic periodontitis," *Archives of Oral Biology*, vol. 57, no. 12, pp. 1609–1614, 2012.

[61] H. Tada, T. Matsuyama, T. Nishioka et al., "Porphyromonas gingivalis gingipain-dependently enhances IL-33 production in human gingival epithelial cells," *PLoS One*, vol. 11, no. 4, article e0152794, 2016.

[62] G. N. Belibasakis, N. Bostanci, and D. Reddi, "Regulation of protease-activated receptor-2 expression in gingival fibroblasts and Jurkat T cells by Porphyromonas gingivalis," *Cell Biology International*, vol. 34, no. 3, pp. 287–292, 2010.

[63] R. Smith, M. Ransjö, L. Tatarczuch et al., "Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation," *Journal of Bone and Mineral Research*, vol. 19, no. 3, pp. 507–516, 2004.

[64] N. Amiable, S. K. Tat, D. Lajeunesse et al., "Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts," *Bone*, vol. 44, no. 6, pp. 1143–1150, 2009.

[65] M. Holzhausen, L. C. Spolidorio, and N. Vergnolle, "Proteinase-activated receptor-2 (PAR2) agonist causes periodontitis in rats," *Journal of Dental Research*, vol. 84, no. 2, pp. 154–159, 2005.

[66] J. J. Reynolds and M. C. Meikle, "Mechanisms of connective tissue matrix destruction in periodontitis," *Periodontology 2000*, vol. 14, no. 1, pp. 144–157, 1997.

[67] T. J. Moraes, R. Martin, J. D. Plumb et al., "Role of PAR2 in murine pulmonary pseudomonal infection," *American Journal of Physiology Lung Cellular and Molecular Physiology*, vol. 294, no. 4, pp. 368–377, 2008.

[68] H. M. Lee, H. Y. Kim, H. J. Kang et al., "Up-regulation of protease-activated receptor 2 in allergic rhinitis," *Annals of Otology, Rhinology & Laryngology*, vol. 116, no. 7, pp. 554–558, 2007.

[69] S. M. McFarlane, M. J. Seatter, T. Kanke, G. D. Hunter, and R. Plevin, "Proteinase-activated receptors," *Pharmacological Reviews*, vol. 53, no. 2, pp. 245–282, 2001.

[70] L. M. Golub, N. Ramamurthy, T. F. McNamara et al., "Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease," *Journal of Periodontal Research*, vol. 19, no. 6, pp. 651–655, 1984.

[71] H. M. Lee, S. G. Ciancio, G. Tüter, M. E. Ryan, E. Komaroff, and L. M. Golub, "Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug," *Journal of Periodontology*, vol. 75, no. 3, pp. 453–463, 2004.

[72] M. Xue, Y. K. Chan, K. Shen et al., "Protease-activated receptor 2, rather than protease-activated receptor 1, contributes to the aggressive properties of synovial fibroblasts in rheumatoid arthritis," *Arthritis & Rheumatology*, vol. 64, no. 1, pp. 88–98, 2012.

[73] D. Zhang, S. Li, L. Hu et al., "Protease-activated receptors expression in gingiva in periodontal health and disease," *Archives of Oral Biology*, vol. 59, no. 4, pp. 393–399, 2014.